Rucaparib Offers Promise for Men with Advanced Prostate Cancer and BRCA1/2 Gene Alterations
Treatment with rucaparib improves progression-free survival (PFS) compared with physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA1/2 alteration.